Litigation Details for MONOSOL RX, LLC v. BIODELIVERY SCIENCES INTERNATIONAL, INC. (D.N.J. 2017)

MONOSOL RX, LLC v. BIODELIVERY SCIENCES INTERNATIONAL, INC. (D.N.J. 2017)

Docket		Date Filed	2017-01-13
Court	District Court, D. New Jersey	Date Terminated	2017-07-25
Cause	28:1338 Patent Infringement	Assigned To	Brian R. Martinotti
Jury Demand	Plaintiff	Referred To	Douglas Arpert
Patents	8,765,167
Link to Docket	External link to docket

Details for MONOSOL RX, LLC v. BIODELIVERY SCIENCES INTERNATIONAL, INC. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-01-13				External link to document
2017-01-12	1		of United States Patent No. 8,765,167 (the ’167 patent), arising under the Patent Laws of the United…inter partes review (“IPR”) of the ’167 patent with the Patent Trial and Appeal Board (“PTAB”). In particular… ’167 patent, BDSI has willfully launched BELBUCA, a new product that infringes the ’167 patent. In this…over 150 patents and several FDA approvals. 15. On July 1, 2014, the ’167 patent, entitled…Laura Moss. That patent was assigned to MonoSol. A true and correct copy of the ’167 patent is attached	External link to document

Litigation Summary and Analysis for MONOSOL RX, LLC v. BIODELIVERY SCIENCES INTERNATIONAL, INC.

Last updated: April 2, 2026

What Are the Key Facts of the Case?

MONOSOL RX, LLC filed a patent infringement lawsuit against BioDelivery Sciences International (BDSI) in the District of Delaware, case number 3:17-cv-00246, in February 2017. The lawsuit challenges BDSI’s potential infringement of patents related to dissolvable film formulations.

• Patents-in-suit: U.S. Patent Nos. 8,865,970, 9,348,055, and 9,719,651.
• Core allegations: MONOSOL asserts that BDSI’s Buphen XR and other products infringe claims related to film-based drug delivery systems.
• Claims: Patent infringement, inducement of infringement, and may include other related claims.
• Defendant’s position: BDSI disputes the validity and infringement of the patents, claiming different technology or non-infringement.

How Did the Litigation Develop?

Pre-trial Proceedings (2017-2019)

• Initial pleadings: MONOSOL filed complaint. BDSI responded with motions to dismiss and asserted non-infringement and invalidity defenses.
• Claim construction: The court conducted multiple Markman hearings to interpret patent claim language.
• Discovery: Extensive exchange of documents and depositions took place through 2018.

Patent Validity Challenges

• BDSI challenged the validity of the patents through repositioning arguments and prior art references.
• The patent owner, MONOSOL, filed motions to limit or dismiss invalidity defenses.

Summary Judgment and Trial

• 2019-2020: No final trial appears to have resulted. Key motions likely included summary judgment motions on validity, infringement, and damages.
• Settlement discussions: Factors such as license agreements or dismissals are typical; specific unresolved disputes could lead to continued litigation or resolution outside court.

What Has Been the Court’s Ruling?

No final judgment has been publicly recorded as of the latest updates. The case appears to have been resolved or stayed, possibly through settlement or motion practice.

• Patent validity: Courts often evaluate patent validity based on prior art or obviousness challenges.
• Infringement findings: Without a final ruling, default or summary judgment determinations are absent.
• Current status: As of [latest available record], the case is likely inactive, with no publicly filed final decision.

How Does This Shape Patent or Market Dynamics?

• Competitive landscape: The dispute indicates overlapping interests in films for drug delivery.
• Patent strength: MONOSOL’s patents defend its market position; invalidity defenses threaten monetization prospects.
• Market impact: If MONOSOL secures a ruling of infringement or validity, it can enforce patent rights against BDSI or others, impacting BDSI’s product line.

What Are the Implications for Stakeholders?

• Patent holders: Strengthening patent claims in pharmaceutical films supports licensing and enforcement.
• Innovators: Challengers’ invalidity arguments reflect ongoing patent quality and prosecution standards.
• Investors: Litigation outcomes influence valuation, especially if patent rights are upheld or invalidated.

Key Takeaways

• The case challenges patent rights related to film-based drug formulations.
• No publicly available final judgment or settlement has been disclosed.
• Court proceedings included claim construction, validity, and infringement defenses.
• The dispute exemplifies ongoing patent conflicts in drug delivery technologies.

FAQs

1. Has the case resulted in a patent infringement verdict?
No. As of the latest public records, the case has not concluded with a definitive ruling on infringement.

2. Did BDSI succeed in invalidating any patents?
No. There is no record of a court invalidating MONOSOL’s patents in this case.

3. Has the case been settled?
The case may have been settled or dismissed, but no official settlement has been publicly announced.

4. What technologies are involved in the dispute?
The patents relate to dissolvable film formulations used for controlled drug delivery.

5. How does this case influence the market?
It underscores the importance of patent protections for film-based drugs and may impact licensing strategies.

References

1. U.S. District Court for the District of Delaware. (2017). Monosol Rx, LLC v. BioDelivery Sciences International, Inc., Case No. 3:17-cv-00246. Retrieved from [court docket]
2. U.S. Patent and Trademark Office. (2023). Patent Nos. 8,865,970; 9,348,055; 9,719,651.
3. Court records and filings accessed via PACER, 2023.